MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.27
-0.66
-6.65%
Closed 16:00 03/02 EST
OPEN
9.85
PREV CLOSE
9.93
HIGH
9.93
LOW
9.23
VOLUME
110.78K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
4.523
MARKET CAP
214.88M
P/E (TTM)
-11.3854
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NeuBase Therapeutics (NBSE) Receives a Buy from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Buy rating on NeuBase Therapeutics (NBSE) on February 11 and set a price target of $17.00. The company's
SmarterAnalyst · 02/15 01:48
DJ NeuBase Therapeutics Price Target Raised to $18.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 02/12 12:01
DJ NeuBase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/12 12:01
10-Q: NEUBASE THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Disclosures Regarding...
Edgar Online - (EDG = 10Q, 10K) · 02/11 22:10
NeuBase Therapeutics EPS beats by $0.05
NeuBase Therapeutics (NBSE): FQ1 GAAP EPS of -$0.18 beats by $0.05.At Dec. 31, 2020, the Company had cash and equivalents of ~$28.0M.Press Release
Seekingalpha · 02/11 21:58
BRIEF-NeuBase Therapeutics Reports Financial Results For The First Quarter Of Fiscal Year 2021
reuters.com · 02/11 21:06
NeuBase Therapeutics Q1 EPS $(0.18) Up From $(0.26) YoY
NeuBase Therapeutics (NASDAQ:NBSE) reported quarterly losses of $(0.18) per share. This is a 30.77 percent increase over losses of $(0.26) per share from the same period last year.
Benzinga · 02/11 21:05
NeuBase Therapeutics 1Q Loss/Shr 18c >NBSE
NeuBase Therapeutics 1Q Loss/Shr 18c >NBSE
Dow Jones · 02/11 21:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBSE. Analyze the recent business situations of NeuBase Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBSE stock price target is 16.80 with a high estimate of 18.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 81
Institutional Holdings: 6.95M
% Owned: 29.98%
Shares Outstanding: 23.18M
TypeInstitutionsShares
Increased
20
226.40K
New
17
244.19K
Decreased
12
268.28K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
President/Chief Executive Officer/Director
Dietrich Stephan
Chief Financial Officer/Treasurer/Secretary
Sam Backenroth
Chief Operating Officer
William Mann
Director
Gines Miralles
Chief Scientific Officer
Curt Bradshaw
Independent Director
Dov Goldstein
Independent Director
Diego Miralles
Independent Director
Franklyn Prendergast
Independent Director
Eric Richman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About NBSE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.